Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector

NCT04628585 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.

NCT NCT04628585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04628585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
Lead sponsor
Genetix Biotherapeutics Inc.
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 21, 2020
Completion date
January 31, 2038
Enrollment
85 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease